These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 11449353)

  • 1. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.
    Benlalam H; Labarrière N; Linard B; Derré L; Diez E; Pandolfino MC; Bonneville M; Jotereau F
    Eur J Immunol; 2001 Jul; 31(7):2007-15. PubMed ID: 11449353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
    Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
    J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
    J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
    Kawakami Y; Eliyahu S; Sakaguchi K; Robbins PF; Rivoltini L; Yannelli JR; Appella E; Rosenberg SA
    J Exp Med; 1994 Jul; 180(1):347-52. PubMed ID: 7516411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope.
    Zajac P; Oertli D; Spagnoli GC; Noppen C; Schaefer C; Heberer M; Marti WR
    Int J Cancer; 1997 May; 71(3):491-6. PubMed ID: 9139889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
    Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
    J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
    Seiter S; Monsurro V; Nielsen MB; Wang E; Provenzano M; Wunderlich JR; Rosenberg SA; Marincola FM
    J Immunother; 2002; 25(3):252-63. PubMed ID: 12000867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
    Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
    J Immunol; 2000 Jan; 164(1):495-504. PubMed ID: 10605047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
    Panelli MC; Bettinotti MP; Lally K; Ohnmacht GA; Li Y; Robbins P; Riker A; Rosenberg SA; Marincola FM
    J Immunol; 2000 Apr; 164(8):4382-92. PubMed ID: 10754339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.
    Larrieu P; Renaud V; Godet Y; Jotereau F; Fonteneau JF
    Cancer Immunol Immunother; 2008 May; 57(5):745-52. PubMed ID: 18097665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
    Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
    Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
    Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes.
    Labarriere N; Pandolfino MC; Raingeard D; Le Guiner S; Diez E; Le Dréan E; Dreno B; Jotereau F
    Int J Cancer; 1998 Oct; 78(2):209-15. PubMed ID: 9754654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
    Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
    Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.